Multi-facetted impulsivity following nigral degeneration and dopamine replacement therapy by Engeln, Michel et al.
lable at ScienceDirect
Neuropharmacology 109 (2016) 69e77Contents lists avaiNeuropharmacology
journal homepage: www.elsevier .com/locate/neuropharmMulti-facetted impulsivity following nigral degeneration and
dopamine replacement therapy
Michel Engeln a, b, 1, Solene Ansquer c, d, e, 1, Emilie Dugast d, e, f, Erwan Bezard a, b,
David Belin f, g, h, 2, Pierre-Olivier Fernagut a, b, *, 2
a Univ. de Bordeaux, Institut des Maladies Neurodegeneratives, UMR 5293, F-33000, Bordeaux, France
b CNRS, Institut des Maladies Neurodegeneratives, UMR 5293, F-33000, Bordeaux, France
c Service de neurologie de l’ho^pital de Poitiers, F-86021, Poitiers, France
d Universite de Poitiers, F-86000, Poitiers, France
e CIC INSERM 1402, CHU de Poitiers, Poitiers, France
f INSERM U1084 Laboratoire de Neurosciences Experimentales et Cliniques, F-86000, Poitiers, France
g Department of Pharmacology, University of Cambridge, CB2 1PD, Cambridge, UK
h Behavioural and Clinical Neuroscience Institute of the University of Cambridge, CB2 3ED, Cambridge, UKa r t i c l e i n f o
Article history:
Received 17 February 2016
Received in revised form
17 May 2016
Accepted 19 May 2016
Available online 20 May 2016
Keywords:
Parkinson
Impulsivity
Alpha-synuclein
Pramipexole
Substantia nigra* Corresponding author. CNRS UMR 5293, Institut
eases, Universite de Bordeaux, 146 rue Leo Saignat, 33
E-mail address: pierre-olivier.fernagut@u-bordeau
1 ME and SA contributed equally.
2 DB and POF contributed equally.
http://dx.doi.org/10.1016/j.neuropharm.2016.05.013
0028-3908/© 2016 The Authors. Published by Elseviea b s t r a c t
Impulse control disorders (ICDs) are debilitating side effects of dopamine replacement therapy (DRT) in
Parkinson’s disease (PD) that severely affect the quality of life of patients. While DRT, the pattern and
extent of neurodegeneration, and prodromic factors of vulnerability (e.g. impulsivity) have all been
hypothesized to play a role in the development of ICDs, their respective, and potentially interacting,
contributions remain to be established. High impulsive (HI), Intermediate (Int) or low impulsive (LI) rats
were identiﬁed based on their performance in both a differential reinforcement of low rate of responding
(DRL) and a ﬁxed consecutive number (FCN) schedules, that operationalize two independent facets of
impulsivity, waiting and action inhibition (motor impulsivity). We investigated whether high impulsivity
trait inﬂuenced the progressive development of a parkinsonian state induced by viral-mediated over-
expression of a-synuclein, and whether impulsivity trait and nigrostriatal neurodegeneration indepen-
dently or jointly inﬂuenced the effects of DRT on impulse control. a-synuclein-induced nigrostriatal
neurodegeneration increased both waiting and motor impulsivity. The D2/D3 dopamine receptor agonist
pramipexole exacerbated motor impulsivity more than waiting. However, the pramipexole-induced in-
crease in waiting impulsivity observed in both sham and lesioned rats, was more pronounced in HI
lesioned rats, which displayed a restricted a-synuclein-induced dopaminergic neurodegeneration. Thus,
a PD-like nigrostriatal lesion increases both motor and waiting impulsivity, but its interaction with a pre-
existing impulsivity trait, which, at the cellular level, confers resilience to dopaminergic neuro-
degeneration, worsens the detrimental effects of D2/D3 dopamine receptor agonists on inhibitory
control.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder char-
acterized both by degeneration of several neuronal populations,e of Neurodegenerative Dis-
076, Bordeaux cedex, France.
x.fr (P.-O. Fernagut).
r Ltd. This is an open access articleincluding dopaminergic neurons in the substantia nigra pars com-
pacta (SNc), and presence of Lewy bodies, the anatomo-
pathological hallmark containing aggregated a-synuclein. Dopa-
mine replacement therapy (DRT) is the ﬁrst-line treatment for
alleviating the motor symptoms of PD but triggers impulse control
disorders (ICDs) in vulnerable individuals (Weintraub et al., 2010).
ICDs include behaviors such as pathological gambling, hypersexu-
ality, binge eating or compulsive shopping, which impinge on the
quality of life of the patients (Voon et al., 2009). The factors
contributing to the development of these debilitating side effects
remain poorly known. If dopamine overdose may account for someunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
M. Engeln et al. / Neuropharmacology 109 (2016) 69e7770of the deleterious effects of DRT on cognitive processes, dopami-
nergic depletion and DRT by deﬁnition co-exist in all PD patients
yet ICDs are only developed by a subset of them (Weintraub et al.,
2010), suggesting a role for other factors, such as impulsivity.
Indeed, contrasting with the parkinsonian personality usually
described as rigid, introverted and slow tempered (Todes and Lees,
1985), novelty seeking, hypomania/extraverted personality, but
also impulsivity have been linked to these compulsive behaviors in
PD (Dagher and Robbins, 2009; Voon and Fox, 2007; Voon et al.,
2011b). PD patients with ICDs display impairments in risk evalua-
tion (Voon et al., 2011a), learning from outcomes (Piray et al., 2014;
Voon et al., 2010a) and increased impulsivity (Voon et al., 2010b),
alongside alterations of fronto-striatal and cortico-subcortical
networks (for review (Tang and Strafella, 2012)).
Impulsivity is a multifaceted construct involving aspects of ac-
tion inhibition (motor impulsivity) and waiting, both contributing
to an inability to withhold prepotent, inappropriate, premature,
responses (D’Amour-Horvat and Leyton, 2014; Dalley et al., 2008;
Dalley and Roiser, 2012). Motor and waiting impulsivity are
related to a dysfunctional dopaminergic modulation of cortico-
striatal networks (Antonelli et al., 2013; Basar et al., 2010; D’Amour-
Horvat and Leyton, 2014; Jentsch et al., 2014): while drugs
enhancing dopamine transmission increase, and dopamine antag-
onists decrease, motor impulsivity, the opposite modulation is
found for waiting impulsivity (reviewed in (D’Amour-Horvat and
Leyton, 2014; Dalley et al., 2008; Dalley and Roiser, 2012)). Thus,
DRT increasing dopamine signaling may exacerbate motor impul-
sivity, while dopaminergic cell-loss would decrease dopamine
levels and increase waiting impulsivity. Such inﬂuences of phar-
macological manipulations of dopamine transmission may be
biased in PD by the asymmetry in denervation between the rela-
tively sparedmesocorticolimbic network and the severely damaged
nigrostriatal pathway. Consequently, DRT may induce a dopami-
nergic overdose of the nucleus accumbens and frontal cortex that
may increase impulsivity (Cools et al., 2003; Gotham et al., 1988) in
a state-dependent manner (Caprioli et al., 2013).
We hypothesized that baseline individual differences in impulse
control may inﬂuence the effects of DRT on impulse control after
nigrostriatal degeneration. To this end, we performed a longitudi-
nal study investigating the respective, and interacting, contribu-
tions of premorbid impulsivity trait, progressive nigrostriatal
dopaminergic neurodegeneration and DRT to the development of
impulse control deﬁcits in rats with viral-mediated overexpression
of a-synuclein. We measured the inﬂuence of the bilateral nigros-
triatal lesion and DRT on inhibitory control of rats displaying high
or low levels of motor and waiting impulsivity as assessed by ﬁxed
consecutive number (FCN) and differential reinforcement of low
rate of responding (DRL) schedules (Jentsch et al., 2014; Rivalan
et al., 2007).2. Materials and methods
2.1. Subjects
Forty-four male Sprague Dawley rats (Janvier, France,
200e225 g at the beginning of the experiment) were housed in
pairs on a reversed 12 h cycle. After 5 days of habituation, theywere
food restricted to 90% of their free feedingweight during behavioral
testing.Waterwas available ad libitum. Experiments were approved
by the Institutional Animal Care and Use Committee of Bordeaux
(CE50, license # 5012099-A) and performed under the European
Union directive (2010/63/EU) on the protection of animals used for
scientiﬁc purposes.2.2. Behavioral procedures
Rats were challenged in two different tasks to assess individual
ability both to inhibit prepotent responses, or wait (DRL), and
maintain ongoing responses (FCN). In the DRL schedule, rats must
wait for a speciﬁc time prior to responding on a manipulandum to
obtain a reward: they have to inhibit a prepotent response. In the
FCN schedule, rats must maintain a response on a ﬁrst manipu-
landum for a ﬁxed number of times before responding on a second
one to obtain a reward. They therefore must not interrupt an
ongoing instrumental response. Inabilities to wait in the DRL or to
maintain the ongoing response chain in the FCN represent waiting
and action impulsivity.
The sequences of training for each task were counter-balanced
to avoid any carry-over effect. Results from preliminary experi-
ments demonstrated that the acquisition and performance in the
DRL and FCN tasks were not inﬂuenced by the nature of the
instrumental response. We therefore used lever presses and nose-
pokes as instrumental responses in the DRL and FCN task, respec-
tively. Experiments were performed in operant chambers (DRL:
29.5 32.5 23.5 cm; FCN: 24 24 26 cm, Med Associates, USA)
enclosed in sound-attenuating ventilated cubicles. Before being
randomly assigned to a FCN-DRL or DRL-FCN group (See Suppl Fig.1
for experimental design), rats were subjected to one session of
magazine training, followed by three successive ﬁxed-ratio 1
schedule sessions (100 lever presses in 45 min) prior to DRL and
FCN training (45-min daily sessions).2.2.1. Differential reinforcement of low rate of responding 20s (DRL-
20s)
Operant chambers were equipped with two levers located on
the right and left side of a food tray. Above each lever was a white
cue light, and a white house-light was on the opposite wall. The
procedurewas adapted from (Fletcher, 1995). Rats obtained a pellet
if at least 5s had elapsed since their previous response on the
reinforced lever (DRL-5s). When the subject reached >80% of re-
wards, the behavioral requirement was incremented to DRL-10s,
-15s and -20s. All rats were tested under DRL-20s for 15 days
before surgery. Premature responses reset the “waiting period” and
were not rewarded. The ﬁrst response was always reinforced. The
following parameters were recorded: number of responses on the
active/inactive levers, number of earned reinforcers, efﬁciency
([number of reinforcers/number of responses]  100), inter-
response time, number of food tray nosepokes, reward collection
latency and seeking behavior (number of visits to the magazine/
number of earned reinforcers).2.2.2. Fixed consecutive number schedules 16 (FCN16)
Operant chambers were equipped with a house-light and 2
holes in which rats could make nosepokes at the right and left side
of a food tray located on the front wall. The procedure was adapted
from (Evenden, 1998; Rivalan et al., 2007). Rats had to respond at
least once (FCN1), three (FCN3), six (FCN6), eight (FCN8), twelve
(FCN12) or sixteen (FCN16) times on the chain poke followed by a
response in the reinforced hole to earn a pellet. Rats reached the
following stage if they performed >80% successful trials during the
session. Rats were tested under FCN16 over 15 days before surgery.
The following parameters were recorded: number of responses on
chain/reinforcement pokes, number of earned pellets, number of
chains (number of responses on the chain poke before responding
on the reinforcement poke), efﬁciency ([number of reinforcement
poke/number of reward earned]  100) and average chain length.
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acquisition of a new task, operant responding and motivation
To exclude any potential confounding effect of lesion-induced
impairments on general motivation or motor/instrumental per-
formance, rats were trained in a different instrumental task (wheel-
turning) under both continuous (FR1) and progressive ratio (PR)
schedules of reinforcement. Operant chambers were equippedwith
one wheel and one 4 cm wide lever installed, respectively, at the
left side and the right side of the back wall, and a food tray at the
center of the front wall. Above the wheel was a white cue light.
Twelve weeks after surgery, animals were subjected to 7 sessions of
Fixed Ratio (FR1) schedule of reinforcement in which they had to
perform 1/2 wheel turn to earn one reward (maximum100 rewards
or 60 min). Subsequently, rats were subjected to a progressive ratio
(PR) of 1e100 pellets maximum to assess their motivation. The
session ended if 15 min had elapsed without reinforcement.
2.3. Viral-mediated lesion
Under isoﬂurane anesthesia, rats were placed in a stereotaxic
frame (Kopf, USA) and received two bilateral injections in the SNc
(Anteroposterior: 5.1 and 5.4; Mediolateral: ±2.2 and ± 2;
Dorsoventral: 7.8, in mm from bregma) of AAV2-9 expressing
human A53T mutant alpha-synuclein driven by the synapsin-I
promoter (n ¼ 23) or AAV2-9 expressing the green ﬂuorescent
protein (GFP; n ¼ 21) as previously described (Bourdenx et al.,
2015; Engeln et al., 2013). Forelimb akinesia was assessed with
the stepping test (Bourdenx et al., 2015; Engeln et al., 2013, 2014)
before and after (4, 8 and 12 weeks) surgery and after drug
challenges.
2.4. Drugs
Levodopa (12 mg/kg þ 15 mg/kg benserazide; i.p. 30 min prior
to tests), apomorphine (0.1 mg/kg; s.c. 15 min prior to tests) and
pramipexole (PPX, 0.3 and 1 mg/kg; i.p. 30 min prior to tests) were
dissolved in 0.9% NaCl (drugs from Sequoia Research Products, UK
excepted apomorphine, Aguettant, France). Doses were chosen as
being efﬁcient to improve motor deﬁcits, as demonstrated with
stepping test performances and previously shown (Engeln et al.,
2013; Rokosik and Napier, 2012). All rats were tested under each
drug condition using a Latin square design separated by washout
sessions.
2.5. Histology
Rats were euthanized with a lethal injection of chloral hydrate
(600mg/kg; VWR, France) and perfusedwith 0.9% NaCl followed by
4% paraformaldehyde (PFA). After 24 h post-ﬁxation in 4% PFA,
brains were cryoprotected in PBS/20% sucrose then frozen. 40 mm-
thick free-ﬂoating coronal sections were collected throughout the
mesencephalon. Immunohistochemistry against tyrosine hydrox-
ylase (TH,Millipore, France) and a-synuclein (Thermoscientiﬁc, UK)
was followed by cresyl violet counterstaining. Stereological esti-
mation of the total number of TH-positive neurons was performed
with the optical fractionator method (Mercator, Explora Nova,
France) (Bourdenx et al., 2015; Engeln et al., 2012, 2013).
2.6. Data and statistical analyses
Data are expressed as mean ± SEM. HI (n ¼ 11), Intermediate
(n ¼ 23) and LI rats (n ¼ 10) were segregated by a K-means cluster
analysis as previously described (Murray et al., 2015), carried-out
on the averaged performance of baseline sessions 46/47 and 45/
46 under FCN and DRL schedules, respectively. These sessionsrepresent the last two of a series of 10 sessions of stable perfor-
mance under the ﬁnal pre-surgery stage (DRL-20s and FCN16). HI,
Int and LI rats were then randomly allocated to the sham or
lesioned group. Analysis of baseline data revealed no signiﬁcant
correlation between FCN and DRL performances (R2 ¼ 0.018,
p > 0.05), indicating that these two tasks reﬂect, as predicted, in-
dependent constructs pertaining to impulse control.
Behavioral differences between groups were analyzed with
multifactorial, repeated measures (RM) analysis of variance
(ANOVA), when appropriate. Assumptions about normality of dis-
tribution and homogeneity of variance were assessed using the
Kolmogorov-Smirnov and Levene tests, respectively. Distributions
were analyzed using chi-squared tests and correlations were tested
using linear regressions. Stereological counts were analyzed using
Student unpaired t-test. The effect of impulsivity on neuronal
counts was analyzed with a two-way ANOVA with lesion and
impulsivity as between-subject factors. Upon signiﬁcant main ef-
fects, post hoc analyses were performed using the Newman-Keuls
test. Statistical signiﬁcance was accepted at p < 0.05.
3. Results
3.1. a-Synuclein-induced motor deﬁcits and dopaminergic
neurodegeneration
Baseline performances under differential reinforcement of low
rate of responding 20s (DRL-20s, waiting impulsivity) and ﬁxed
consecutive number schedules 16 (FCN16, impulsive action) were
used to segregate low impulsive (LI), intermediate (Int) and high
impulsive (HI) subpopulations. Rats were then randomly allocated
to the sham or lesioned group (See Suppl Fig. 1 for experimental
design).
In all rats, viral-mediated expression of a-synuclein in the SNc
elicited progressive bilateral motor deﬁcits (Lesion  Weeks: F3,
126 ¼ 365.7; p < 0.0001) signiﬁcant at 4 weeks post-surgery, and
worsening at 8 and 12 weeks (p < 0.001, Fig. 1A). 12 weeks post-
surgery, HI, Int and LI lesioned rats displayed similar motor deﬁ-
cits (Fig. 1B) that were improved by all dopaminergic drug tested
(each drug was tested on representative samples of 5e8 animals
containing LI, Int and HI rats; Suppl Fig. 2).
Stereological counts revealed that overexpression of a-synuclein
resulted in an overall 49% lesion restricted to the SNc (t ¼ 5.79,
df¼ 42; p < 0.0001; Fig.1C). The extent of the lesionwas dependent
upon pre-existing impulsivity (Lesion  Impulsivity: F2, 38 ¼ 6.01;
p < 0.01) and HI rats displayed a milder lesion (19%, non signiﬁ-
cantly different from sham animals) than Int (62%) or LI (52%)
(p < 0.05; Fig. 1D, E). This difference was speciﬁc to impulsivity trait
as it was attributable neither to off-target injections of the viral
vector nor to a lack of a-synuclein expression (Fig. 1E), as revealed
by prominent a-synuclein immunoreactivity in the SNc of all rats.
3.2. Effect of dopaminergic neurodegeneration on inhibitory control
Successful trials in the DRL task were inﬂuenced by impulsivity
trait and the lesion (Lesion  Session: F29, 1218 ¼ 2.21; p < 0.0001,
Block  Impulsivity: F4, 76 ¼ 7.86; p < 0.001 (three blocks of 10
sessions: pre-surgery, post-surgery and pre-drug)). Sham rats dis-
played a decrease in the number of rewards obtained over the ﬁrst
6 sessions post-surgery (p < 0.05) but resumed their pre-surgery
levels by session 8 (Fig. 2A). LI and Int rats were initially more
affected than HI animals post-surgery (p < 0.05) and Int rats never
recovered their pre-surgery performances (p < 0.05; Fig. 2B). While
lesioned animals showed a similar alteration of waiting impulsivity,
most of them never recovered their pre-surgery performance
(p < 0.05) and performed worse than sham animals (last pre-drug
Fig. 1. a-Synuclein-induced motor deﬁcits and dopaminergic neurodegeneration. A.
Stepping test performances at Baseline (0), 4, 8 and 12 weeks after viral-mediated
expression of a-synuclein in the substantia nigra (p < 0.001 for each time-point; 2-
way RM-ANOVA); B. Motor performances at 12 weeks post-surgery for the 3 sub-
groups of each population (*p < 0.001 from sham; 2-way ANOVA); C. Stereological
counts of tyrosine hydroxylase (TH) positive cells in the Substantia nigra pars compacta
(SNc) and the ventral tegmental area (VTA), *p < 0.0001 (t-test; all impulsivity traits
included); D. Magnitude of the nigral lesion in Low impulsive (LI), Intermediate (Int)
and High impulsive (HI) animals (*p < 0.05 from Lesioned LI and Int; 2-way ANOVA); F.
Representative mesencephalic sections of one sham rat and lesioned rats of each
impulsivity subgroup (upper panel) stained for TH. Low magniﬁcation pictures of a-
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recover their pre-surgery performance (Fig. 2B). Similar results
were observed for efﬁciency (Lesion  Session: F29, 1218 ¼ 3.28;
p < 0.0001). Sham rats exhibited a transient decrease in perfor-
mance during the ﬁrst 6 post-surgery sessions (p < 0.05), returning
subsequently to their pre-surgery level (Fig. 2C). In marked
contrast, lesioned rats remained impaired post-surgery (p < 0.05
from the last pre-surgery session) with an efﬁciency signiﬁcantly
lower than sham animals at post-surgery sessions 8e10 and pre-
drug sessions 1, 2, and 10 (p < 0.05 for each). Efﬁciency on the
last session before pre-surgery, post-surgery and before drug
treatment (pre-drug) according to pre-existing impulsivity trait is
shown on Suppl Fig. 3.
Rewards obtained in the FCN task were also affected by the
lesion (Lesion  Session: F29, 1218 ¼ 4.35; p < 0.0001) and impul-
sivity trait (Block  Sessions  Impulsivity: F44, 763 ¼ 1.95
p < 0.0001). The number of rewards earned was decreased in sham
animals for the ﬁrst 3 post-surgery sessions for FCN16 (p < 0.05).
When the FCN schedule was tailored for each animal to reach the
baseline schedule (FCN16), performances progressively increased
and sham rats recovered their pre-surgery scores by the last pre-
drug session (Fig. 2D). In marked contrast, lesioned rats never
recovered their pre-surgery level (p < 0.05), performing consis-
tently worse than sham rats (p < 0.05, Fig. 2E). Regardless of
impulsivity trait, all lesioned rats displayed a long-term deﬁcit
following surgery (p < 0.05 for both post-surgery and pre-drug
periods; Fig. 2E). Consequently, FCN chain length was affected by
both the lesion (Lesion  Session: F29, 1218 ¼ 12.11; p < 0.0001) and
impulsivity trait (Block  Sessions  Impulsivity: F44, 396 ¼ 2.31;
p < 0.0001). In sham animals, performances initially lower than
pre-surgery (p < 0.05) recovered (Fig. 2F). In lesioned animals,
chain length remained signiﬁcantly lower from both baseline and
sham animals in all post-surgery sessions (p < 0.05, Fig. 2F). Chain
length on the last session before pre-surgery, post-surgery and
before drug treatment (pre-drug) according to pre-existing
impulsivity trait is shown on Suppl Fig. 3. During post-surgery,
35% of lesioned rats were under FCN3 compared with 5% of sham
animals (p < 0.05), while 76% of sham rats were under FCN8
compared with 43% of lesioned rats (p < 0.05). Similarly, during the
pre-drug period, only 26% of lesioned rats achieved the baseline
criterion of FCN16 compared with 76% of sham rats (p < 0.05). This
differential proﬁle of performance in the FCN task over the course
of the experiment is represented in Suppl Fig. 4 as the represen-
tativity of the sham and lesioned populations across the different
FCN stages before surgery, after surgery and before drug challenge.
Altogether, the long-term deﬁcits displayed by lesioned rats
illustrate the exacerbation by a nigral lesion of waiting impulsivity
and impulsive actions. Importantly, such deﬁcits were not attrib-
utable to motor, instrumental or motivational deﬁcits. Indeed, to
exclude a possible confounding effect of motor, motivational or
instrumental conditioning impairments or motivation, rats were
trained in a new task (wheel-turning) under both continuous (FR1)
and progressive ratio (PR) schedules of reinforcement (Fig. 3).
Neither lesion (Fig. 3A) nor impulsivity levels (Fig. 3B) inﬂuenced
the acquisition of wheel-turning behavior over 7 days. Similarly, no
effect of lesion (Fig. 3C) or impulsivity levels (Fig. 3D) were
observed on breakpoints in the PR task.synuclein immunostaining in each subgroup (middle panel; scale bar: 100 mm). High
magniﬁcation images of the corresponding LI, Int and HI animals (lower panel; scale
bar: 20 mm) showing a-synuclein accumulation in all subgroups. Sh ¼ sham; LI ¼ low
impulsive; Int ¼ intermediate; HI ¼ high impulsive. Data represent mean ± SEM.
Sham: LI: n ¼ 5, Int: n ¼ 12, HI: n ¼ 4; Lesioned: LI: n ¼ 6, Int: n ¼ 11, HI: n ¼ 6.
Fig. 2. Nigral dopaminergic lesion decreases inhibitory control. A. Rewards obtained in DRL20 in baseline (pre surgery), for the 10 ﬁrst sessions after surgery (post surgery) and for the
10 last sessions before drug challenge (pre drug) (all impulsivity traits included; 2-way ANOVA); B. DRL performances before surgery, after surgery and before drug treatment
according to pre-existing impulsivity trait; C. Efﬁciency (rewards/responses) in DRL20 before surgery, after surgery and before drug challenge (2-way ANOVA); D. Rewards obtained
in FCN16 before surgery, after surgery and before drug challenge (all impulsivity traits included; 2-way ANOVA); E. FCN performances before surgery, after surgery and before drug
treatment according to pre-existing impulsivity trait; F. Chain length in FCN16 at the 3 periods (3-way ANOVA). Data represent mean ± SEM. p < 0.05 *from baseline, ¤ from sham,
Sham: LI: n ¼ 5, Int: n ¼ 12, HI: n ¼ 4; Lesioned: LI: n ¼ 6, Int: n ¼ 11, HI: n ¼ 6.
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Impulse control in the DRL task was impaired by dopamine
receptor agonists but not by L-Dopa (lesion  Treatment: F4,
210 ¼ 8.35; p < 0.001) (Fig. 4). The number of rewards collected was
decreased by apomorphine in all lesioned rats (p < 0.001 vs. saline)
and by PPX, at both doses in all rats (ps < 0.001 vs. saline). While
the effect of PPX treatment was not dependent upon pre-existing
impulsivity trait in sham rats, a trend in lesioned animals
(Treatment  Impulsivity: F8, 80 ¼ 1.80; p ¼ 0.08) suggested po-
tential differences between HI, Int and LI rats. ANOVAs with planed
comparisons carried out on LI vs. HI rats revealed that HI rats under
0.3 mg/kg PPX received less rewards (F1, 20 ¼ 4.50; p < 0.05;
Fig. 4A).
Sham animals presented a decreased efﬁciency
(Treatment lesion: F4, 210¼ 10.03; p < 0.0001) following both PPX
doses (ps < 0.01, Fig. 4B). Despite a decrease in rewards obtainedand an increase in reward-seeking comparable to sham animals
(67.35 ± 10.48 vs. 46.77 ± 8.65 tray nosepokes/rewards for PPX
1 mg/kg; Treatment  lesion: F4, 210 ¼ 3.16; p < 0.05), lesioned
animals did not display an altered efﬁciency.
Linear regressions revealed that animals with lower lesion levels
made more premature responses under both PPX doses (r2 ¼ 0.4,
p < 0.001 and r2¼ 0.36, p < 0.01 respectively; Fig. 5). Hence, despite
a milder loss of dopaminergic neurons, HI rats were more sensitive
to the disinhibitory effects of PPX than LI rats. In sham rats, pre-
mature responses increased dose-dependently with PPX regardless
of impulsive trait (Treatment: F4, 90 ¼ 32.63; p < 0.0001,
Treatment  impulsivity interaction: F8, 90 < 1; Fig. 5).3.4. Effects of dopaminergic treatments on impulsive actions
In the FCN test, the number of rewards collected and chain
length were reduced by PPX (Lesion  Treatment: F4, 210 ¼ 4.84;
Fig. 3. Effects of bilateral SNc lesion on task acquisition, operant responding and moti-
vation: A. Over the 7 sessions, no difference was observed between sham and lesioned
rats (all impulsivity traits included; 2-way RM-ANOVA) B. No difference in the total
number of rewards obtained was seen between subpopulations of both groups for the
last FR1 session (2-way ANOVA). C. The number of responses required to obtain a pellet
increased according to the following progression (1, 3, 4, 6, 8, 11, 13, 16, 19, 23, 27, 32,
38, 44, 50, 58, 67, 77, 88, 100). No difference in breakpoint (the maximum number of
wheel turn) was reported between both groups (along the 3 PR sessions (all impul-
sivity traits included; 2-way RM-ANOVA). D. No difference in breakpoints was seen
between subpopulations of both sham and lesioned groups for the last PR session (2-
way ANOVA). Sham: LI: n ¼ 5, Int: n ¼ 12, HI: n ¼ 4; Lesioned: LI: n ¼ 6, Int: n ¼ 11, HI:
n ¼ 6.
Fig. 4. Pramipexole differentially increases waiting impulsivity depending on SNc lesion
and impulsivity trait. A. Rewards obtained in DRL20 according to the dopaminergic
drug; B. Efﬁciency (reward/response) in DRL20 during drug challenge. Data represent
mean ± SEM; 2-way ANOVAs; *p < 0.01 from saline, # from Low impulsive. LI: Low
impulsive, Int: Intermediate, HI: High impulsive; PPX: Pramipexole, Apo: Apomor-
phine. Sham: LI: n ¼ 5, Int: n ¼ 12, HI: n ¼ 4; Lesioned: LI: n ¼ 6, Int: n ¼ 11, HI: n ¼ 6.
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apomorphine or L-Dopa (Fig. 6). Sham and lesioned rats displayed a
drastic decrease in the number of rewards obtained and chain
length with both PPX doses (ps < 0.001 vs saline, Fig. 6A and B,
respectively) the extent of which preventing investigating any in-
ﬂuence of impulsivity. Indeed, 43% or 76% of sham and 43.5% or 52%
of lesioned rats obtained no reward after injection of 0.3 or 1mg/kg
PPX, respectively (ps < 0.01 vs. saline). Neither apomorphine nor L-
Dopa altered FCN performances in sham and lesioned rats.4. Discussion
Impulsivity has been described in PD (Dagher and Robbins,
2009) but the underlying pathophysiological substrates and their
etiological contribution to ICDs remain poorly known (Poletti and
Bonuccelli, 2012). Waiting impulsivity and impulsive actions
(D’Amour-Horvat and Leyton, 2014) are well documented in
neurologically intact subjects and are modulated by dopamine,
particularly with themesolimbic andmesocortical pathways. In PD,
dopaminergic function is altered by the nigrostriatal dopaminergic
loss but also by DRT, and clinical studies have provided opposite
ﬁndings on the contribution of these factors to altered inhibitorycontrol (Bastiaens et al., 2013; Vriend et al., 2015; Weintraub et al.,
2013). Besides methodological differences, these discrepancies may
stem from the multifactorial etiology of ICDs and the heterogeneity
of the disease process (Nombela et al., 2014). This longitudinal
study was therefore designed to disentangle the respective con-
tributions of nigrostriatal neurodegeneration, DRT and baseline
impulsivity in the emergence of behavioral deﬁcits relevant to ICDs.
Our results provide the ﬁrst evidence that impulsivity is asso-
ciated with a differential vulnerability to a-synuclein-induced
dopaminergic neurodegeneration, with HI rats being less sensitive
than Int and LI rats. This is in agreement with the observation that
impulsivity is decreased in mice lacking a-synuclein (Pena-Oliver
et al., 2012, 2014), suggesting that highly impulsive subjects can
cope with higher levels of a-synuclein that non impulsive. Impul-
sivity is associated with decreased midbrain D2/D3 autoreceptor
availability and increased amphetamine-induced striatal dopamine
Fig. 5. Premature responses under PPX are dependent on impulsivity and lesion severity. Linear regressions represent premature responses according to lesion compared to sham rats;
Lower right panel represent the number of premature responses for sham rats according to the different dopaminergic drugs (2-way ANOVA). Data represent mean ± SEM;
*p < 0.0001. LI: Low impulsive, Int: Intermediate, HI: High impulsive; PPX: Pramipexole, Apo: Apomorphine; THþ: Tyrosine Hydroxylase positive. Sham: LI: n ¼ 5, Int: n ¼ 12, HI:
n ¼ 4; Lesioned: LI: n ¼ 6, Int: n ¼ 11, HI: n ¼ 6.
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dividuals dopamine neurons may be able to sustain a higher ac-
tivity, metabolic demand and proteostasis, which may overall help
them to copemore efﬁcientlywith alpha-synuclein overexpression.
The present results further demonstrate that nigrostriatal
degeneration affects several dimensions of impulsivity. Lesioned
animals displayed a major decline in DRL efﬁciency indicating
increased waiting impulsivity. However, performances of LI and Int
lesioned rats were more affected by the lesion than those of HI rats,
a difference potentially attributable to the milder nigrostriatal
degeneration observed in the latter. The nigrostriatal lesion also
drastically increased impulsive actions. Even though the differ-
ences in DRL performances between impulsivity subgroups could
be related to a different magnitude of nigral degeneration, the
similar FCN impairment between HI and LI lesioned rats despite a
milder dopaminergic loss in HI rats suggest that impulsive in-
dividuals may be more sensitive to the deleterious effect of dopa-
minergic loss on impulsive actions. These results also suggest that
mesencephalic dopaminergic nuclei may differentially contribute
to impulsive actions depending on impulsive trait.
Collectively, our results indicate that a neurodegenerative pro-
cess affecting the nigrostriatal pathway in rats, akin to the neuro-
degeneration observed in PD patients, increases independent
dimensions of impulsivity (waiting impulsivity and impulsive ac-
tions). This deleterious effect of the nigrostriatal lesion on impulse
control seemed to be more pronounced on impulsive actions than
on waiting impulsivity, particularly regarding HI lesioned rats. Our
results also suggest that premorbid impulsivity may interact with
the disease process in PD and differentially inﬂuence the nature of
the inhibitory control deﬁcits developing after nigrostriatal
degeneration. Nigrostriatal degeneration can also affect other di-
mensions of impulsivity, as recently shown with increased impul-
sive choice in a delay discounting task following dorsolateral
striatal dopaminergic loss (Tedford et al., 2015). While decreasedinhibitory control may not be sufﬁcient per se to trigger ICDs in PD
patients, our results suggest that dopaminergic neurodegeneration
can affect behavioral traits to amuch greater extent than previously
thought (Bastiaens et al., 2013; Weintraub et al., 2013).
Dopamine depletion can also decreasewillingness to sustain the
effort to obtain rewards (Cawley et al., 2013), a motivational deﬁcit
that cannot account for the observed results since lesioned rats did
not display instrumental or motivational deﬁcits as assessed using
a separate series of food-reinforced instrumental tasks.
We further evidenced that the inﬂuence of DRT over waiting
impulsivity depends on impulsivity trait in lesioned rats only.
Consistent with clinical studies that identiﬁed D2/D3 agonists as a
major risk factor for ICD (Voon et al., 2006; Weintraub, 2009), the
D2/D3 agonist PPX was the most deleterious DRT, increasing
waiting impulsivity in both sham and lesioned groups. While all
sham rats were equally susceptible to this deleterious effect, a
different patternwas found in lesioned rats. Indeed, HI lesioned rats
that were the only lesioned animals able to recover their pre-lesion
performance in the DRL task, obtained less rewards than their LI
counterparts when treated with the lowest PPX dose. These results
suggest that the lesion, DRT and impulsive trait can interact to
further increase waiting impulsivity in high impulsive individuals.
Surprisingly, efﬁciency was not signiﬁcantly reduced by DRT in
lesioned rats albeit they expressed a similar reward-seeking
behavior as sham rats. Efﬁciency as a measure of impulsivity can
however carry limitations, as unfocused behaviors could mask poor
inhibitory capacities (Hill et al., 2012; Sanabria and Killeen, 2008).
Further highlighting multiple contributions to the emergence of
greater inhibitory control deﬁcits, premature responses under PPX
in the DRL task negatively correlated with lesion severity, with HI
animals displaying more premature responses being those with the
mildest lesion.
The non-selective dopamine receptor agonist apomorphine
increased impulsive actions in all lesioned rats. Hypokinesia in PD
Fig. 6. Pramipexole increases impulsive action regardless of SNc lesion or impulsivity
trait. A. Rewards obtained in FCN according to the dopaminergic drugs; B. Chain length
in FCN during drug challenge. Data represent mean ± SEM; 2-way ANOVAs; *p < 0.001
from saline. LI: Low impulsive, Int: Intermediate, HI: High impulsive; PPX: Prami-
pexole, Apo: Apomorphine. Sham: LI: n ¼ 5, Int: n ¼ 12, HI: n ¼ 4; Lesioned: LI: n ¼ 6,
Int: n ¼ 11, HI: n ¼ 6.
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activation (Mallet et al., 2006). The activation of this pathway by
apomorphine may have resulted in a sudden increased activity
leading to poor DRL performances. Such result is consistent with
previous work showing that both D1 and D2 receptors stimulation
mediate behavioral disinhibition and premature responding in the
5-choice serial reaction time task (van Gaalen et al., 2006).
While studies using discounting tasks in human showed that
impulsive choices were related to D2/3 agonists exclusively in pa-
tients presenting ICDs (Voon et al., 2010b), our results show that
PPX drastically increased impulsive actions independently of a
dopaminergic lesion or impulsivity trait. Since impulsive actions
depend heavily upon dopaminergic signaling in mesolimbic path-
ways (Basar et al., 2010) that were spared both in normal and
lesioned rats, a dopamine overdose of fronto-limbic networks
following PPX administrationmay underlie this effect. Nonetheless,these results show that D2/3 agonists trigger impulsive behaviors
in both SNc lesioned and non-lesioned subjects as evidenced in PD
(Weintraub et al., 2010) and the restless legs syndrome (Voon et al.,
2011c).
Importantly, our results showing that PPX differentially alters
impulsive actions and waiting impulsivity are in agreement with a
recent study demonstrating that dimensions of impulsivity are not
equally affected by PPX in PD patients (Antonelli et al., 2014). This
effect of PPX is also in line with clinical and neurocomputational
results demonstrating that enhanced D2 stimulation favors a “Go”
bias and decreases the ability to suppress inappropriate responses
(“NoGo”) (Frank et al., 2004). Although the enhancement of
impulsivity reported here may represent a core feature underlying
the propensity of D2/D3 agonists to induce ICDs, PPX also alters
learning from outcomes (Piray et al., 2014; Voon et al., 2010a) and
biases choices towards risky options both in rats (Johnson et al.,
2011; Rokosik and Napier, 2012) and PD patients (Voon et al.,
2011a), thus disrupting cognitive processes that are necessary for
optimal decision making and altered in patients with ICDs.5. Conclusions
This study in a bilateral rat model of PD shows that nigrostriatal
dopaminergic neurodegeneration, DRT and pre-morbid impulsivity
interact, and differentially contribute to alter inhibitory control.
Nigrostriatal neurodegeneration increases impulsivity but waiting
impulsivity and impulsive actions are differentially affected
depending on baseline impulsivity trait. Indeed, a-synuclein over-
expression increases impulsive actions but not waiting impulsivity
in individuals with high basal impulsivity but impairs global
inhibitory control in rats with low basal impulsivity. Despite over-
expression of a-synuclein, HI animals present a reduced nigros-
triatal degeneration compared to LI rats, supporting the hypothesis
that behavioral traits can be associated with a differential vulner-
ability of dopaminergic neurons to degeneration. In addition to
establishing the face validity and clinical relevance of this model to
study the pathophysiology of impulsivity and of non-motor side
effects of DRT in PD, we show that if impulsive actions are highly
sensitive to PPX regardless of a dopaminergic loss or impulsivity
trait, PPX-induced increase in waiting impulsivity depends upon
the combination of nigral degeneration and pre-existing impul-
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